CVS Health Stock Lags but Holds Significant Value Potential
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy CVS?
Source: Fool
- Valuation Appeal: CVS stock trades at under 11 times forward earnings, with a remarkable 126.5% revenue growth over the past decade, reporting a record $402.1 billion in sales for 2025, and management forecasts adjusted EPS of $7.00 to $7.20 for 2026, indicating strong long-term growth potential.
- Stable Cash Flow: CVS froze its dividend at $0.50 per share from 2017 to 2021 but has increased it by 33% since 2022, with a current yield of 3.46% and a payout ratio of 43.5%, demonstrating the company's ability to sustain and grow its dividend.
- Medicare Rate Increase: The CMS raised Medicare payment rates to 2.48%, which is expected to enhance margins for CVS's Aetna unit, with anticipated revenue of at least $400 billion this year, showcasing improved profitability in the healthcare insurance sector.
- Market Share Opportunities: The closure of Rite Aid stores presents CVS's over 9,000 retail locations with a chance to expand market share, and the upcoming first-quarter earnings report could lead to a dividend increase or stock buyback program, further appealing to value and income investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CVS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CVS
Wall Street analysts forecast CVS stock price to rise
17 Analyst Rating
16 Buy
1 Hold
0 Sell
Strong Buy
Current: 78.860
Low
91.00
Averages
96.71
High
105.00
Current: 78.860
Low
91.00
Averages
96.71
High
105.00
About CVS
CVS Health Corporation is a health solutions company. The Company's segments include Health Care Benefits, Health Services, Pharmacy & Consumer Wellness and Corporate/Other. The Health Care Benefits segment offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, PDPs and Medicaid health care management services. The Health Services segment provides a full range of pharmacy benefit management (PBM) solutions through its CVS Caremark operations and delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its CVS Pharmacy retail locations and, through its infusion operations, provides ancillary pharmacy services including pharmacy patient care programs, and vaccination administration, and sells a wide assortment of health and wellness products and general merchandise.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aetna Accelerates Prior Authorization Reform for Better Care Access
- Standardization Progress: Aetna has standardized 88% of its prior authorization volume, exceeding industry commitments and demonstrating its leadership in simplifying access to care for patients and providers, thereby strengthening its competitive position among national health plans.
- Rapid Approval Efficiency: Over 95% of eligible prior authorizations are approved within 24 hours, with 83% processed in real time, surpassing AHIP's 2027 industry commitment of 80%, which not only enhances customer satisfaction but also optimizes the responsiveness of healthcare services.
- Automation Tool Utilization: Aetna has eliminated over 1 million provider calls through automation and digital tools, significantly reducing administrative burdens and allowing healthcare providers to focus more on patient care, thus improving overall service efficiency.
- Integrated Medical Decisions: Aetna becomes the first national payer to integrate medical and pharmacy decisions into single, condition-specific reviews, with newly launched bundled prior authorization programs enhancing the experience for patients and providers, marking its innovation and leadership in the prior authorization space.
See More
Aetna Leads Prior Authorization Reform for Improved Patient Care
- Standardization of Prior Authorization: Aetna has standardized 88% of its prior authorization volume, exceeding industry commitments and maintaining the fewest medical services requiring prior authorization among national health plans, significantly enhancing service efficiency for patients and providers.
- Process Modernization: By becoming the first national payer to integrate medical and pharmacy decisions into single, condition-specific reviews, Aetna is redefining the prior authorization process, aiming to accelerate access to care and reduce unnecessary delays.
- Launch of New Programs: Newly launched bundled prior authorization programs, including a comprehensive musculoskeletal offering based on earlier cancer bundles, aim to create a more seamless experience for patients and providers, thereby improving overall healthcare service quality.
- Broad Customer Base: Aetna serves approximately 37 million people with health insurance products and related services, covering employer groups, individuals, and governmental units, showcasing its extensive influence and market leadership in the health management sector.
See More
Investors Should Focus on Undervalued Healthcare Stocks
- Market Opportunity Identification: CNBC's Jim Cramer urged investors to look at undervalued sectors, particularly healthcare stocks, which appear more attractive amidst the tech surge, providing diversification for portfolios.
- CVS Health's Market Advantage: Cramer highlighted CVS Health's benefits from a changing competitive landscape, as rivals like Rite Aid disappear and Walgreens scales back, allowing CVS to effectively increase market share through its insurance arm Aetna and numerous retail locations.
- Cardinal Health's Transformation: Cramer noted that Cardinal Health has been unfairly punished without clear reason, yet the company is transitioning from a traditional drug distributor to higher-growth services, particularly in supporting specialty medical practices, showcasing future growth potential.
- Johnson & Johnson's Strong Foundation: Cramer emphasized Johnson & Johnson's robust balance sheet and pipeline of potential blockbuster drugs, coupled with CEO Stephen Hemsley's return, which has bolstered market confidence in its ability to sustain growth.
See More
Investors Should Focus on Undervalued Healthcare Stocks
- Market Opportunity: Jim Cramer highlighted that despite the S&P 500 and Nasdaq hitting new highs, healthcare stocks are undervalued due to solid fundamentals, suggesting investors focus on these overlooked areas for portfolio diversification.
- CVS Health's Competitive Edge: Cramer emphasized that CVS Health is benefiting from a changing competitive landscape, as rivals like Rite Aid disappear and Walgreens scales back, positioning CVS to capture market share with its insurance arm Aetna and extensive retail locations.
- Cardinal Health's Transformation: Cramer noted that Cardinal Health has been unfairly punished without clear reasons, but the company is shifting from its traditional drug distribution role to higher-growth services, particularly in supporting specialty medical practices.
- Johnson & Johnson's Strong Outlook: Cramer pointed out Johnson & Johnson's robust balance sheet and potential blockbuster pipeline, while the return of CEO Stephen Hemsley has stabilized UnitedHealth Group and restored confidence in its growth trajectory.
See More
Ro Launches Major Price Cuts, Increasing Competitive Pressure on HIMS
- Intensified Price Competition: Ro's Body Membership program offers up to 50% discounts for prepaid patients, translating to annual savings of $900, significantly lowering treatment costs and posing a threat to HIMS's market share.
- HIMS Stock Decline: Following Ro's price cuts, HIMS shares fell 3% in premarket trading on Thursday, marking its second consecutive day of losses, reflecting investor concerns over intensified competition as the stock price dropped to $29.01.
- Shifting Market Dynamics: With Amazon expanding its GLP-1 management program through One Medical, Bank of America Securities warned that this could exert long-term pressure on HIMS's weight-loss revenues, particularly among patients seeking lower-cost prescription renewals.
- Product Line Expansion: HIMS is diversifying its treatment portfolio by launching estrogen patch treatments for menopause and perimenopause care, indicating a strategic intent to broaden its offerings in response to market competition and patient needs.
See More
CVS Health Stock Lags but Holds Significant Value Potential
- Valuation Appeal: CVS stock trades at under 11 times forward earnings, with a remarkable 126.5% revenue growth over the past decade, reporting a record $402.1 billion in sales for 2025, and management forecasts adjusted EPS of $7.00 to $7.20 for 2026, indicating strong long-term growth potential.
- Stable Cash Flow: CVS froze its dividend at $0.50 per share from 2017 to 2021 but has increased it by 33% since 2022, with a current yield of 3.46% and a payout ratio of 43.5%, demonstrating the company's ability to sustain and grow its dividend.
- Medicare Rate Increase: The CMS raised Medicare payment rates to 2.48%, which is expected to enhance margins for CVS's Aetna unit, with anticipated revenue of at least $400 billion this year, showcasing improved profitability in the healthcare insurance sector.
- Market Share Opportunities: The closure of Rite Aid stores presents CVS's over 9,000 retail locations with a chance to expand market share, and the upcoming first-quarter earnings report could lead to a dividend increase or stock buyback program, further appealing to value and income investors.
See More
Aetna Accelerates Prior Authorization Reform for Better Care Access
- Standardization Progress: Aetna has standardized 88% of its prior authorization volume, exceeding industry commitments and demonstrating its leadership in simplifying access to care for patients and providers, thereby strengthening its competitive position among national health plans.
- Rapid Approval Efficiency: Over 95% of eligible prior authorizations are approved within 24 hours, with 83% processed in real time, surpassing AHIP's 2027 industry commitment of 80%, which not only enhances customer satisfaction but also optimizes the responsiveness of healthcare services.
- Automation Tool Utilization: Aetna has eliminated over 1 million provider calls through automation and digital tools, significantly reducing administrative burdens and allowing healthcare providers to focus more on patient care, thus improving overall service efficiency.
- Integrated Medical Decisions: Aetna becomes the first national payer to integrate medical and pharmacy decisions into single, condition-specific reviews, with newly launched bundled prior authorization programs enhancing the experience for patients and providers, marking its innovation and leadership in the prior authorization space.
See More
Aetna Leads Prior Authorization Reform for Improved Patient Care
- Standardization of Prior Authorization: Aetna has standardized 88% of its prior authorization volume, exceeding industry commitments and maintaining the fewest medical services requiring prior authorization among national health plans, significantly enhancing service efficiency for patients and providers.
- Process Modernization: By becoming the first national payer to integrate medical and pharmacy decisions into single, condition-specific reviews, Aetna is redefining the prior authorization process, aiming to accelerate access to care and reduce unnecessary delays.
- Launch of New Programs: Newly launched bundled prior authorization programs, including a comprehensive musculoskeletal offering based on earlier cancer bundles, aim to create a more seamless experience for patients and providers, thereby improving overall healthcare service quality.
- Broad Customer Base: Aetna serves approximately 37 million people with health insurance products and related services, covering employer groups, individuals, and governmental units, showcasing its extensive influence and market leadership in the health management sector.
See More
Investors Should Focus on Undervalued Healthcare Stocks
- Market Opportunity Identification: CNBC's Jim Cramer urged investors to look at undervalued sectors, particularly healthcare stocks, which appear more attractive amidst the tech surge, providing diversification for portfolios.
- CVS Health's Market Advantage: Cramer highlighted CVS Health's benefits from a changing competitive landscape, as rivals like Rite Aid disappear and Walgreens scales back, allowing CVS to effectively increase market share through its insurance arm Aetna and numerous retail locations.
- Cardinal Health's Transformation: Cramer noted that Cardinal Health has been unfairly punished without clear reason, yet the company is transitioning from a traditional drug distributor to higher-growth services, particularly in supporting specialty medical practices, showcasing future growth potential.
- Johnson & Johnson's Strong Foundation: Cramer emphasized Johnson & Johnson's robust balance sheet and pipeline of potential blockbuster drugs, coupled with CEO Stephen Hemsley's return, which has bolstered market confidence in its ability to sustain growth.
See More
Investors Should Focus on Undervalued Healthcare Stocks
- Market Opportunity: Jim Cramer highlighted that despite the S&P 500 and Nasdaq hitting new highs, healthcare stocks are undervalued due to solid fundamentals, suggesting investors focus on these overlooked areas for portfolio diversification.
- CVS Health's Competitive Edge: Cramer emphasized that CVS Health is benefiting from a changing competitive landscape, as rivals like Rite Aid disappear and Walgreens scales back, positioning CVS to capture market share with its insurance arm Aetna and extensive retail locations.
- Cardinal Health's Transformation: Cramer noted that Cardinal Health has been unfairly punished without clear reasons, but the company is shifting from its traditional drug distribution role to higher-growth services, particularly in supporting specialty medical practices.
- Johnson & Johnson's Strong Outlook: Cramer pointed out Johnson & Johnson's robust balance sheet and potential blockbuster pipeline, while the return of CEO Stephen Hemsley has stabilized UnitedHealth Group and restored confidence in its growth trajectory.
See More
Ro Launches Major Price Cuts, Increasing Competitive Pressure on HIMS
- Intensified Price Competition: Ro's Body Membership program offers up to 50% discounts for prepaid patients, translating to annual savings of $900, significantly lowering treatment costs and posing a threat to HIMS's market share.
- HIMS Stock Decline: Following Ro's price cuts, HIMS shares fell 3% in premarket trading on Thursday, marking its second consecutive day of losses, reflecting investor concerns over intensified competition as the stock price dropped to $29.01.
- Shifting Market Dynamics: With Amazon expanding its GLP-1 management program through One Medical, Bank of America Securities warned that this could exert long-term pressure on HIMS's weight-loss revenues, particularly among patients seeking lower-cost prescription renewals.
- Product Line Expansion: HIMS is diversifying its treatment portfolio by launching estrogen patch treatments for menopause and perimenopause care, indicating a strategic intent to broaden its offerings in response to market competition and patient needs.
See More
CVS Health Stock Lags but Holds Significant Value Potential
- Valuation Appeal: CVS stock trades at under 11 times forward earnings, with a remarkable 126.5% revenue growth over the past decade, reporting a record $402.1 billion in sales for 2025, and management forecasts adjusted EPS of $7.00 to $7.20 for 2026, indicating strong long-term growth potential.
- Stable Cash Flow: CVS froze its dividend at $0.50 per share from 2017 to 2021 but has increased it by 33% since 2022, with a current yield of 3.46% and a payout ratio of 43.5%, demonstrating the company's ability to sustain and grow its dividend.
- Medicare Rate Increase: The CMS raised Medicare payment rates to 2.48%, which is expected to enhance margins for CVS's Aetna unit, with anticipated revenue of at least $400 billion this year, showcasing improved profitability in the healthcare insurance sector.
- Market Share Opportunities: The closure of Rite Aid stores presents CVS's over 9,000 retail locations with a chance to expand market share, and the upcoming first-quarter earnings report could lead to a dividend increase or stock buyback program, further appealing to value and income investors.
See More
